Table 2.
Clinicopathological characteristics of patients with gastric cancer based on human epidermal growth factor receptor 2 expression, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide mutations and Epstein-Barr virus infection n (%)
| HER2 | PIK3CA | EBV | ||||||||
| Positive (n = 20) | Negative (n = 211) | P value | Mutation (n = 20) | Wild type (n = 211) | P value | Positive (n = 18) | Negative (n = 204) | P value | ||
| Sex | Male | 15 (75) | 142 (67) | 0.48 | 13 (65) | 144 (68) | 0.77 | 14 (78) | 138 (68) | 0.38 |
| Female | 5 (25) | 69 (33) | 7 (35) | 70 (32) | 4 (22) | 66 (32) | ||||
| Age | Median | 69 (50-84) | 71 (25-91) | 0.26 | 71 (25-85) | 70 (38-91) | 0.40 | 72 (48-90) | 70 (38-91) | 0.41 |
| Location | Cardias | 10 (50) | 72 (34) | 0.49 | 5 (25) | 77 (36) | 0.31 | 8 (44) | 73 (36) | 0.70 |
| Body | 5 (25) | 57 (27) | 4 (20) | 58 (27) | 5 (28) | 55 (27) | ||||
| Antrum | 5 (25) | 78 (37) | 10 (50) | 73 (35) | 5 (28) | 75 (37) | ||||
| Unknown | 0 | 4 (2) | 1 (5) | 2 (1) | 0 | 1 (0) | ||||
| Depth | T2 | 12 (60) | 113 (54) | 0.48 | 8 (40) | 117 (55) | 0.15 | 12 (67) | 106 (52) | 0.35 |
| T3 | 8 (40) | 84 (40) | 9 (45) | 83 (39) | 6 (33) | 85 (42) | ||||
| T4 | 0 | 14 (6) | 3 (15) | 11 (5) | 0 | 13 (6) | ||||
| L/N meta | N0 | 5 (25) | 60 (28) | 0.71 | 4 (20) | 61 (29) | 0.37 | 3 (17) | 57 (28) | 0.28 |
| N+ | 14 (70) | 144 (68) | 16 (80) | 142 (67) | 14 (77) | 140 (69) | ||||
| N1 | 5 (25) | 68 (32) | 8 (40) | 65 (31) | 8 (44) | 63 (31) | ||||
| N2 | 6 (30) | 50 (24) | 6 (30) | 50 (24) | 2 (11) | 53 (26) | ||||
| N3 | 3 (15) | 26 (12) | 2 (10) | 27 (13) | 4 (22) | 24 (12) | ||||
| Unknown | 1 (5) | 7 (3) | 0 | 8 (4) | 1 (6) | 7 (3) | ||||
| Stage | I | 5 (25) | 44 (21) | 0.89 | 1 (5) | 48 (23) | 0.14 | 3 (17) | 41 (20) | 0.98 |
| II | 3 (15) | 42 (20) | 7 (35) | 38 (18) | 4 (22) | 39 (19) | ||||
| III | 6 (30) | 76 (36) | 8 (40) | 74 (35) | 6 (33) | 75 (37) | ||||
| IV | 5 (25) | 46 (22) | 4 (20) | 47 (22) | 4 (22) | 46 (23) | ||||
| Unknown | 1 (5) | 3 (1) | 0 | 4 (2) | 1 (6) | 3 (1) | ||||
| Lauren | Intestinal | 15 (75) | 98 (46) | 0.05 | 14 (70) | 99 (47) | 0.13 | 5 (28) | 105 (51) | 0.04 |
| histotype | Diffuse | 5 (25) | 107 (51) | 6 (30) | 106 (50) | 13 (72) | 93 (46) | |||
| LELC | 0 | 6 (3) | 2 (10) | 4 (2) | 5 (28) | 0 | ||||
| Others | 0 | 6 (3) | 0 | 6 (3) | 0 | 6 (3) | ||||
| MSI | 2 (10) | 28 (13) | 0.72 | 10 (50) | 20 (9) | < 0.01 | 1 (6) | 26 (13) | 0.36 | |
| pAkt | 16 (84) | 103 (51) | < 0.01 | 12 (63) | 107 (53) | 0.37 | 8 (47) | 103 (52) | 0.69 | |
| 3 yr OS (%) | 29.4 | 59.2 | 0.24 | 57.3 | 56.8 | 0.59 | 57.4 | 57.3 | 0.98 | |
MSI: Microsatellite instability; LELC: Lymphoepithelioma-like carcinoma; HER2: Human epidermal growth factor receptor 2; PIK3CA: Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide mutations; EBV: Epstein-Barr virus; pAkt: Phospho Akt; OS: Overall survival.